We searched the literature for eligible studies published from inception up to 16 August 2022 through PubMed, EMBASE, Cochrane Library, Scopus and ClinicalTrials.gov. Two methodologically trained researchers will select the qualified studies for data extraction independently. Cochrane Risk of Bias tool will be used to assess the risk of bias in included studies. Statistical heterogeneity will be computed by Cochrane X2 and I2 tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Publication biases will be evaluated by Begg\'s and Egger\'s tests. The quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation system. The RevMan V.5.3 and Stata V.14.0 software will be applied for statistical analyses.
Ethical approval will not be required for this systematic review because the data used are not linked to the individual patient. The results of this review will be disseminated by being published in a peer-reviewed journal.
CRD42022310414.
方法:我们搜索了从开始到2022年8月16日通过PubMed发表的合格研究的文献,EMBASE,科克伦图书馆,ScopusandClinicalTrials.gov.两名经过方法学训练的研究人员将独立选择合格的研究进行数据提取。Cochrane偏差风险工具将用于评估纳入研究的偏差风险。统计异质性将通过CochraneX2和I2检验来计算。将进行敏感性分析以评估结果的稳定性。出版偏见将通过Begg\和Egger\的测试来评估。证据质量将通过建议分级评估来评估,开发和评估系统。将应用RevManV.5.3和StataV.14.0软件进行统计分析。
背景:本系统评价不需要伦理批准,因为所使用的数据与患者个体无关。本评论的结果将通过发表在同行评审的期刊上进行传播。
UNASSIGNED:CRD42022310414。